TG Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

TG Therapeutics

01/08/2023 14:32

* TG Therapeutics Inc  TGTX.OQ  reported a quarterly
adjusted loss
of 34 cents​​ per share for the quarter ended in June. The mean
expectation of eight analysts for the quarter was for a loss
of 25 cents per share.
    * Revenue rose 2,606.1% to $16.07 million from a year ago;
analysts expected $17.45 million. 
    * TG Therapeutics Inc's reported EPS for the quarter was a
loss
of 34 cents​.
    * The mean earnings estimate of analysts had risen by
about 8.8%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates 
    * TG Therapeutics Inc shares had fallen by 16.7% this
quarter and
gained 74.9% so far this year.
    * The company reported a quarterly loss of $47.61 million.
    * Wall Street's median 12-month price target for TG
Therapeutics
Inc is $36.75 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and 2 "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 1 at 01:31 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.25          -0.34          Missed
 Mar. 31 2023      -0.37          -0.28          Beat
 Dec. 31 2022      -0.26          -0.39          Missed
 Sep. 30 2022      -0.34          -0.26          Beat